Co-Diagnostics Inc.

Co-Diagnostics Inc. is a molecular diagnostics company that focuses on the development, manufacturing, and marketing of innovative diagnostic technology. Primarily, the company is engaged in creating cost-effective, high-quality diagnostic solutions for infectious diseases, including tests for COVID-19, Zika, tuberculosis, and influenza. Co-Diagnostics utilizes its proprietary CoPrimer™ technology to enhance the accuracy of PCR (polymerase chain reaction) tests, setting a new standard in molecular diagnostics by optimizing DNA or RNA detection. The firm plays a critical role in the healthcare sector, notably impacting public health monitoring and response by providing essential tools for early disease detection and management. Operating globally, Co-Diagnostics aims to improve accessibility to advanced diagnostics, especially in regions with limited resources. With headquarters in Salt Lake City, Utah, the company was founded in 2013, amid growing demand for reliable molecular testing solutions. Its presence is significant in the market as it addresses the urgent need for precise diagnostic tests, which are essential for controlling disease outbreaks and improving patient outcomes worldwide.